Status:
COMPLETED
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Advanced Breast Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to learn about the safety and efficacy of Dasatinib in combination with Capecitabine for patients with advanced breast cancer, and who have received treatment with a taxan...
Eligibility Criteria
Inclusion
- For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.
- Inclusion Criteria:
- Female with advanced breast cancer previously treated with a taxane and an anthracycline
- No pleural or pericardial effusion
- Not receiving anticoagulants
Exclusion
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2012
Estimated Enrollment :
52 Patients enrolled
Trial Details
Trial ID
NCT00452673
Start Date
June 1 2007
End Date
October 1 2012
Last Update
March 24 2015
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
City Of Hope National Medical Center
Duarte, California, United States, 91010-3000
2
Northwestern University Feinberg School Of Medicine
Chicago, Illinois, United States, 60611
3
New York Presbyterian Hospital
New York, New York, United States, 10065
4
Seattle Cancer Care Alliance
Seattle, Washington, United States, 98109-1023